Table 2.
Characteristics of LTBI patients with a rheumatic disease.
| Gender | Diagnosis | Disease duration (years) | Biological medicine (months) | Prednisone dose (mg/day) | DMARDsa | CRPb mg/l | ESRc mm/h |
|---|---|---|---|---|---|---|---|
| M | RAd (M05.8) | 26 | Etanercept (32) | 5 | Mtxe, SASPf, and HCQg | 3 | 17 |
| F | RA (M06.0) | 28 | Etanercept (59) | 5 | – | 11 | 36 |
| M | RA (M05.8) | 16 | –k | 10 | Mtx | 87 | 39 |
| F | RA (M06.0) | 9 | Etanercept (1) | – | – | 10 | 8 |
| F | RA (M05.8) | 6 | – | 5 | Mtx, leflunomide, and HCQ | <3 | 2 |
| F | RA (M05.8) | 20 | Rituximab (12) | 5 | – | 29 | 34 |
| F | JRAh (M08.0) | 64 | Rituximab (23) | 7.5 | – | 18 | 13 |
| F | RA (M05.8) | 8 | – | 5 | Leflunomide | 71 | 41 |
| F | RA (M05.8) | 8 | – | – | SASP | 13 | 22 |
| M | RA (M05.8) | 7 | Rituximab (24) | 5 | Mtx and HCQ | 72 | 57 |
| M | Vascultis (L95.8) | 1 | – | 5 | HCQ | 7 | 5 |
| M | RA (M05.8) | 18 | – | 7.5 | Mtx and CyAi | <3 | 26 |
| F | SPAj (M45) | 4 | Golimumab (1) | – | Mtx and SASP | 4 | 12 |
aDisease-modifying antirheumatic drug.
bC-reactive protein.
cErythrosyte sedimentation rate.
dRheumatoid arthritis.
eMethotrexate.
fSulfasalazine.
gHydroxychloroquine.
hJRA, juvenile rheumatoid arthritis.
iCyclosporine.
jSPA ankylosing spondylitis.
kEtanercept stopped 9 months earlier (used for 21 months).